| P50 | author | In-Kyu Park | Q50528088 |
| | Santhosh Kalash Rajendrakumar | Q61079331 |
| P2093 | author name string | Chong-Su Cho | |
| | Yong-Kyu Lee | |
| | Chang Seong Kim | |
| | Bijay Singh | |
| | Vishnu Revuri | |
| | Adityanarayan Mohapatra | |
| P2860 | cites work | Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity | Q26782131 |
| | Enhancing Cancer Immunotherapy Via Activation of Innate Immunity | Q26796313 |
| | Polymeric nanoparticles for pulmonary protein and DNA delivery | Q33560960 |
| | Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy | Q33572965 |
| | Melanoma vaccines: mixed past, promising future | Q34235476 |
| | The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice | Q34774050 |
| | Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc | Q35958174 |
| | Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy | Q36269694 |
| | Combinations of TLR ligands: a promising approach in cancer immunotherapy | Q37383587 |
| | TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination | Q37461812 |
| | In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy | Q37465136 |
| | MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy | Q37737313 |
| | Mannosylated and histidylated LPR technology for vaccination with tumor antigen mRNA. | Q38072382 |
| | Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines | Q38166484 |
| | Adoptive immunotherapy for cancer or viruses | Q38178359 |
| | TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects | Q38195599 |
| | Melanoma immunotherapy | Q56896842 |
| | Antigen-adjuvant effects of icariin in enhancing tumor-specific immunity in mastocytoma-bearing DBA/2J mice | Q88517545 |
| | Local Delivery of CTGF siRNA with Poly(sorbitol-co-PEI) Reduces Scar Contraction in Cutaneous Wound Healing | Q90857081 |
| | Evolving role of tumor antigens for future melanoma therapies. | Q38232855 |
| | Nanoparticle-based immunotherapy for cancer | Q38282133 |
| | Nanoparticulate immunotherapy for cancer | Q38598181 |
| | Towards an evidence based approach for the development of adjuvanted vaccines | Q38649954 |
| | Multifunctional nanoparticles for cancer immunotherapy | Q38744042 |
| | Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer | Q38804315 |
| | Albumin Incorporation in Polyethylenimine-DNA Polyplexes Influences Transfection Efficiency | Q38812963 |
| | Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer | Q38849614 |
| | Suppression of tumor growth in lung cancer xenograft model mice by poly(sorbitol-co-PEI)-mediated delivery of osteopontin siRNA. | Q38856885 |
| | Dendritic-tumor fusion cells in cancer immunotherapy | Q38892387 |
| | Induction of long-term immunity against respiratory syncytial virus glycoprotein by an osmotic polymeric nanocarrier. | Q38967264 |
| | Selective transfection with osmotically active sorbitol modified PEI nanoparticles for enhanced anti-cancer gene therapy. | Q38989704 |
| | Poly(I:C) exhibits an anti-cancer effect in human gastric adenocarcinoma cells which is dependent on RLRs. | Q39096689 |
| | Nanoparticles for tumor immunotherapy | Q39190035 |
| | High gene transfer by the osmotic polysorbitol-mediated transporter through the selective caveolae endocytic pathway | Q39329404 |
| | Melanoma antigens and related immunological markers | Q39364839 |
| | Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier | Q39669738 |
| | Delivery of whole tumor lysate into dendritic cells for cancer vaccination | Q39997888 |
| | Clinical trials in melanoma patients with brain metastases | Q40283801 |
| | Poly (I:C) enhances the anti-tumor activity of canine parvovirus NS1 protein by inducing a potent anti-tumor immune response. | Q40516283 |
| | Cytotoxic impacts of linear and branched polyethylenimine nanostructures in a431 cells | Q40553481 |
| | Therapeutic in situ autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial | Q42220239 |
| | Cancer statistics, 2018. | Q47191906 |
| | Current challenges for cancer vaccine adjuvant development. | Q48160317 |
| | Nanomaterials for cancer immunotherapy. | Q48646732 |
| | Highly Efficient Intracellular Protein Delivery by Cationic Polyethyleneimine-Modified Gelatin Nanoparticles. | Q49805895 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P577 | publication date | 2018-09-25 | |
| P1433 | published in | Polymers | Q57337397 |
| P1476 | title | Self-Assembled, Adjuvant/Antigen-Based Nanovaccine Mediates Anti-Tumor Immune Response against Melanoma Tumor | |
| P478 | volume | 10 | |